. intolerance). Ibrutinib is The present gold normal therapy for individuals with relapsed/refractory condition, determined by the final results of many section I-III trials, one hundred fifteen–119 but this is also switching for 2 most important good reasons: (i) an increasing proportion of individuals presently obtain ibrutinib as frontline the